, Serratia liquefaciens, and Serratia marcescens. C includes the following species or organisms: Pseudomonas aeruginosa, Acinetobacter baumannii, Acinetobacter lwoffii, Bordetella bronchiseptica, Achromobacter xylosoxidans, Flavobacterium IIb and Flavobacterium species and Stenotrophomonas maltophilia. Consisting of Fusobacterium nucleatum, Brivanib BMS-540215 Fusobacterium necrophorum, Fusobacterium and naviforme. Includes e Prevotella melaninogenica and Prevotella intermedia. f Includes Prevotella bivia, Prevotella buccae, and Prevotella oris. g Enth the species Propionibacterium, Propionibacterium granulosum and Propionibacterium avidum lt. h Includes the following species: Peptostreptococcus anaerobius, Peptostreptococcus asaccharolyticus, Peptostreptococcus species and other Peptostreptococcus prevotii.
I shall include the following types: Bilophila wadsworthia, lentum Eubacterium, Bacteroides fragilis, Bacteroides capillosus, Bacteroides MLN8237 uniformis, gracilis, Campylobacter, Clostridium and paraputrificum. d NA, not available. Cefuroxime 0.06 0.25 32 0.03 32 8 .125 1 clindamycin Veillonella species ABT 492 0.002 2 0.03 1 0.06 4 0.5 moxifloxacin levofloxacin 4 0.03 4 0.06 2 0.062 0.125 2 gatifloxacin penicillin G 0.03 8 2 8 amoxicillin clavulanate Cefuroxime 4 2 4 0015 0.25 16th April 16 0.5 0.06 0.25 0.03 492 4 Other clindamycin anaerobesi ABT 0.002 0.06 0.03 Naj moxifloxacin levofloxacin first August 8 0.5 8 0.5 0.03 NA 0.03 NA NA gatifloxacin penicillin G on 16 January NA 0.03 0.03 2 0.5 amoxicillin clavulanate Cefuroxime 0.015 NA NA NA 32 2 32 0.
03 0125 3010 NOTES Clindamycin Antimicrob. Agents Chemother. and M. catarrhalis, ABT 492 had a MIC 90 of 0.008 g / ml Zhanel et al. ABT to note 492, highly active against 630 St Strains of H. influenzae and 430 M. catarrhalis have-St Strains. ABT 492 with 0.5 g / ml effective against two St Strains of S. aureus resistant Staphylococcus. Studies of the anaerobic activity of t by ABT 492 were up to now U Only limited. Nilius et al. examined the activity t of ABT 492 against 16 St strains of B. fragilis strains and 12 St of Clostridium difficile and found MIC90s of 0.12 and 0.015 g / ml Barry et al. reported activity th of ABT 492 against 20 isolates of B. fragilis, Prevotella 11 isolates, 12 isolates of Clostridium perfringens, and 10 isolates of C. difficult.
Tested in our study, ABT 492 good results against anaerobes, with an isolate of B. uniformis, the g 4 492/ml ABT to inhibit all other isolates and inhibited with 2 g / ml amoxicillin clavulanate performed well against all anaerobes and many aerobic bacteria studied, with the exception of the family Enterobacteriaceae and nonfermenting Gram-negative bacteria as described above. Levofloxacin showed good activity T against most aerobic and anaerobic isolates many Nebenh Select, with the exception of 8% of the anaerobes. Moxifloxacin and gatifloxacin had anything similar activity Th against both aerobic and anaerobic bacteria. ABT 492 is the active ingredient with a wider range and improved efficacy compared to those of currently available quinolones tested. It deserves a sp Direct assessment as a therapeutic alternative for acute sinusitis and chronic. This study was funded in part by a grant from Abbott Laboratories. We Judee H. Knight and Alice E. Goldstein thank for help. ABT 492, an experimental fluoroquinolone, is aimed at both IV DNA gyrase and topoisomerase Thus was on the quinolone